USP7 and cancer: Evaluation of XL177A and its enantiomer, XL177B, as a negative control, across a broad panel of 484 cancer cell lines and in a series of targeted confirmatory studies, found that TP53 mutational status predicted response to selective USP7 inhibition across multiple cancer lineages.